InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy
NCT: NCT06411548 · COMPLETED
Brief Summary
This is a 24-hour, randomized, crossover, single-center trial where participants are randomized to either start with the InsuLearn intervention or the usual care (UC) intervention. In the InsuLearn intervention, insulin doses are optimized using data collected in a 4-weeks at home data collection period.
Frequently Asked Questions
What is InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy?
InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy is a clinical trial registered under NCT06411548. Current status: COMPLETED.
What is the status of NCT06411548?
The current status of NCT06411548 (InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy) is: COMPLETED.
When did InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy start?
InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy started on 2025-03-27.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.